Actinium-225 alpha therapy — a hard asset, read end to end
Most valuation tools price a drug as a probability-weighted cash-flow stream and stop. This one treats two structural facts as first-class value drivers: who holds the capital, and who controls the supply. An Actinium-225 radioligand from a capital-constrained junior is the asset where both bite at once — so it’s the clearest way to show the reasoning, not just the result.
01Probability of success
The chain starts at a 4.7% phase-1 base rate and lands at 5.5% after seven named multipliers — every one carrying its own citation, so the number is auditable rather than asserted.
base rate4.7%
modality: radiopharmaceutical×0.95
biomarker enrichment×1.20
target validated×1.15
Orphan Drug Designation×1.05
Fast Track Designation×1.03
◆ reflexivity: constrained×0.88
◆ supply constraint: severe×0.93
final LOA5.5%
◆ the two path-dependency rows
The diamonds are the distinctive part. A constrained sponsor takes the chain down
×0.88 (
reflexivity: a raise-dependent junior signals weakly and is forced into trial-design compromises), and severe isotope supply takes another
×0.93 (a supply bottleneck is execution risk, not just a commercial cap). Generic frameworks model neither — they treat capital and supply as someone else’s problem.
honest provenance
Note the modality row: ×0.95 is labelled an “Asclepius estimate, no BIO/Informa cohort.” Radiopharmaceuticals post-date the 2021 industry dataset, so the tool says so rather than borrowing a citation it isn’t entitled to. Every multiplier renders its real source — including the ones that admit a gap.
provenance● citedexternal dataset / study / named deal◇ estimatethe tool's own reasoned magnitude, honestly labeled — never a borrowed citation
02Valuation — and the ceiling generic DCF misses
The risk-adjusted rNPV is a $18M floor — what a 5.5%-LOA phase-1 asset is worth today once you weight the whole cash-flow tree by the chance it ever launches.
the supply ceiling on revenue
Here’s the move a DCF tool can’t make: severe supply doesn’t just add risk to the PoS, it caps achievable peak sales. The model holds nominal peak at $1,500M but applies a ×0.65 supply ceiling, so the revenue line is built on $975M. You can’t sell isotopes you can’t make — the ceiling belongs on the revenue side, not buried in the discount rate.
03Comparables — and a $18M ↔ $3B bracket
The asset routes to a curated oncology · radiopharmaceutical cohort (RayzeBio/BMS, Fusion/AZ, POINT/Lilly), median 2.0× EV/peak-sales — not the kinase-TKI fallback an off-the-shelf comp set would have forced. At 2.0× the cohort implies roughly $3,000M of strategic value.
reading the bracket
So the framework brackets the asset between an $18M risk-adjusted floor and a ~$3B strategic ceiling. That gap is the thesis: it’s the de-risking premium an acquirer pays once the isotope-supply and phase-1 risks resolve — and the supply ceiling is precisely what keeps the upper bound soft until the supply chain is proven out.
04The call
cautiousmedium conviction
Watch, don’t chase — yet. The biology and the regulatory path are real, and the radiopharma cohort says the strategic ceiling is genuine. But the two path-dependencies net-move the call down: a constrained sponsor (×0.88) is one failed raise from a fire sale, and severe isotope supply (×0.93 on PoS, −35% on peak) caps the very upside the comp set is pricing. The asset is a buy at the right basis once supply de-risks — not before.
kill criterion (falsifiable)
A failure to secure a multi-year Ac-225 supply agreement (or in-house production milestone) before the phase-2 start flips this to avoid — without scalable isotope, the $3B ceiling is fiction and the $18M floor is the whole story.